EP4720281A2 - Inhibiteurs d'expression et/ou de fonction - Google Patents

Inhibiteurs d'expression et/ou de fonction

Info

Publication number
EP4720281A2
EP4720281A2 EP24727438.4A EP24727438A EP4720281A2 EP 4720281 A2 EP4720281 A2 EP 4720281A2 EP 24727438 A EP24727438 A EP 24727438A EP 4720281 A2 EP4720281 A2 EP 4720281A2
Authority
EP
European Patent Office
Prior art keywords
strand
seq
inhibitor
nucleosides
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24727438.4A
Other languages
German (de)
English (en)
Inventor
James LONGDEN
Amy MCCARTHY
Ines DE SANTIAGO DOMINGOS DE JESUS
Alexandre DEBACKER
Natalie PURSELL
Alex Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tangram Therapeutics PLC
Original Assignee
Tangram Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tangram Therapeutics PLC filed Critical Tangram Therapeutics PLC
Publication of EP4720281A2 publication Critical patent/EP4720281A2/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/332—Abasic residue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne des inhibiteurs, et des compositions contenant des inhibiteurs, et leurs utilisations dans le traitement ou la prévention d'une maladie liée à ICFEr, telle qu'une cardiopathie ischémique.
EP24727438.4A 2023-05-26 2024-05-24 Inhibiteurs d'expression et/ou de fonction Pending EP4720281A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP23175699 2023-05-26
US202463571886P 2024-03-29 2024-03-29
PCT/EP2024/064367 WO2024245930A2 (fr) 2023-05-26 2024-05-24 Inhibiteurs d'expression et/ou de fonction

Publications (1)

Publication Number Publication Date
EP4720281A2 true EP4720281A2 (fr) 2026-04-08

Family

ID=91186754

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24727438.4A Pending EP4720281A2 (fr) 2023-05-26 2024-05-24 Inhibiteurs d'expression et/ou de fonction

Country Status (8)

Country Link
EP (1) EP4720281A2 (fr)
JP (1) JP2026520457A (fr)
KR (1) KR20260029506A (fr)
CN (1) CN122206797A (fr)
AU (1) AU2024279697A1 (fr)
IL (1) IL324890A (fr)
MX (1) MX2025014063A (fr)
WO (1) WO2024245930A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025202455A2 (fr) * 2024-03-29 2025-10-02 E-Therapeutics Plc Inhibiteurs d'expression et/ou de fonction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003233634A1 (en) * 2002-05-20 2003-12-12 Pharmacia Corporation Antisense modulation of glucocorticoid receptor expression
EP2305813A3 (fr) * 2002-11-14 2012-03-28 Dharmacon, Inc. SIRNA fonctionnel et hyperfonctionnel
WO2006006948A2 (fr) * 2002-11-14 2006-01-19 Dharmacon, Inc. Methodes et compositions permettant de selectionner des arnsi presentant une fonctionnalite amelioree
WO2006002022A2 (fr) * 2004-06-15 2006-01-05 Immusol Incorporated Compositions et methodes utiles pour le traitement de l'hyperglycemie
US11560563B2 (en) 2018-04-05 2023-01-24 Silence Therapeutics Gmbh SiRNAs with vinylphosphonate at the 5′ end of the antisense strand
WO2022162161A1 (fr) * 2021-01-30 2022-08-04 E-Therapeutics Plc Composés oligonucléotidiques conjugués, leurs procédés de fabrication et leurs utilisations

Also Published As

Publication number Publication date
AU2024279697A1 (en) 2026-01-08
MX2025014063A (es) 2026-03-02
IL324890A (en) 2026-01-01
CN122206797A (zh) 2026-06-12
WO2024245930A3 (fr) 2025-03-06
WO2024245930A2 (fr) 2024-12-05
KR20260029506A (ko) 2026-03-04
JP2026520457A (ja) 2026-06-23

Similar Documents

Publication Publication Date Title
US20250368992A1 (en) Nucleic acid compounds
CA3249744A1 (fr) Inhibiteurs d’expression et/ou de fonction
WO2024165571A2 (fr) Inhibiteurs d'expression et/ou de fonction
KR20250043473A (ko) 핵산 화합물
US20250320494A1 (en) Inhibitors of expression and/or function
WO2024023254A1 (fr) Composés d'acides nucléiques
WO2024023267A2 (fr) Composés d'acides nucléiques
WO2024245930A2 (fr) Inhibiteurs d'expression et/ou de fonction
AU2023313029A1 (en) Double stranded nucleic acid compounds inhibiting zpi
EP4707391A1 (fr) Composés d acides nucléiques
EP4652283A1 (fr) Composés d'acide nucléique pour l'inhibition zpi
US20250388897A1 (en) Nucleic acid compounds
WO2025125576A2 (fr) Inhibiteurs d'expression et/ou de fonction
WO2025021989A1 (fr) Inhibiteurs de l'expression et/ou de la fonction
CA3258247A1 (fr) Composés d'acides nucléiques
WO2025202455A2 (fr) Inhibiteurs d'expression et/ou de fonction
EP4662315A2 (fr) Inhibiteurs d'expression et/ou de fonction
OA21722A (en) Compositions and methods for inhibiting expression of Prekallikrein (PKK) protein.

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251203

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR